Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0006142 (breast cancer)
 160,383 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The possibility that meningioma growth may be related to female sex hormone levels is suggested by several lines of evidence. Meningiomas are twice as common in women as in men, have been observed to wax and wane with pregnancy, and are positively associated with breast cancer. A physiological explanation for these phenomena is provided by the finding of steroid hormone receptors in meningiomas. However, unlike breast cancer, meningiomas are much more commonly positive for progesterone receptors than for estrogen receptors. The authors initiated a study on long-term oral therapy of unresectable meningiomas with the antiprogesterone mifepristone (RU486). Fourteen patients received mifepristone in daily doses of 200 mg for periods ranging from 2 to 31+ months (greater than or equal to 6 months in 12 patients). Five patients have shown signs of objective response (reduced tumor measurement on computerized tomography scan or magnetic resonance image, or improved visual field examination). Three have also experienced subjective improvement (improved extraocular muscle function or relief from headache). The side effects of long-term mifepristone therapy have been mild. Fatigue was noted in 11 of the 14 patients. Other side effects included hot flashes in five patients, gynecomastia in three, partial alopecia in two, and cessation of menses in two. Long-term therapy with mifepristone is a new therapeutic option that may have efficacy in cases of unresectable benign meningioma.
 ...
PMID:Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. 203 44

Abnormalities at the tissue receptor level may be important in the pathophysiology of pubertal macromastia, which may be unilateral or bilateral. We studied breast tissue removed from seven boys of age 16-17 years, five with bilateral and two with unilateral gynaecomastia. We confirmed that their physical features, karyotype, and plasma concentrations of testosterone, oestradiol, LH, FSH, and prolactin were all normal for adolescent males. Oestrogen and progesterone receptors were measured with a steroid binding (dextran coated charcoal) assay which was used for breast cancer receptor studies. Oestrogen receptors were not detectable in any of the 12 breasts studied. Progesterone receptors were detectable at a low level in two patients with bilateral gynaecomastia, one breast from each patient. We conclude that although the development of bilateral or unilateral male macromastia in puberty may yet be mediated by a local tissue receptor abnormality, this disorder is probably not mediated by an abnormal increase in oestrogen receptor number.
 ...
PMID:Oestrogen and progesterone receptors in men with bilateral or unilateral pubertal macromastia. 233 7

A retrospective study has been undertaken of 104 men with breast cancer, all of them having a follow-up period of at least 5 years. In 78 cases a histological diagnosis was obtained. The preferred treatment for operable cases was radical mastectomy, in which 60 per cent positive axillary nodes were found. Five-year survival is 54 per cent and the disease-free interval is 42 per cent. Local recurrence occurred in 26 per cent and 16 per cent had developed distant metastases. The overall results are similar to those in the literature with the exception of those for stage III who did better in this series. The generally held beliefs that Klinefelter's syndrome is the strongest predisposing factor to developing male breast cancer and that gynaecomastia is not a premalignant condition are supported by this study. Comparison of results from this series, with those of women of the same age having breast cancer leads to the conclusion that the prognosis in male breast cancer is no worse than for women with comparable disease.
 ...
PMID:A retrospective study of male breast cancer in Holland. 299 94

Early detection and correct diagnosis of breast cancer is necessary and an important determinant of prognosis. Clinical echography is increasingly being used as it offers a high degree of diagnostic accuracy and no physical hazards such as x-ray mammography. Ultrasonic tissue characterization study is an important factor in determining and refining diagnostic criteria and for developing new ultrasonic diagnostic equipment in clinical breast echography. Therefore, various echographic characteristics and their ultrasonic tissue characterization were analysed in various types of breast tumors such as medullary carcinoma, papillary carcinoma, scirrhous carcinoma, malignant lymphoma, lymphatic infiltration, benign cyst, fibroadenoma, cystosarcoma phylloides, gynecomastia and nodular fibrosis with fat necrosis, in routine clinical echograms.
 ...
PMID:Echographic characteristics and ultrasonic tissue characterization in breast tumor. 300 56

A case-control study was conducted in Los Angeles County, CA, of 75 male breast cancer cases aged 20-74 yr at diagnosis to investigate the role of a number of suspected risk factors. The study involved both interviews and laboratory measurements. Factors under study included fertility and marital history, obesity, alcohol and cigarette consumption, use of drugs known or suspected of causing gynecomastia, family history of breast cancer, history of radiation exposure to the upper body, sex chromatin analysis, serum levels of prolactin, testosterone, estrone, estradiol and sex-hormone-binding globulin, as well as urinary levels of estrone, estradiol, and estriol. Two patients versus no controls tested positive for sex chromatin and were excluded from further analyses. The only statistically significant risk factor identified was greater weight of the cases at age 30; a man who weighed 80 or more kg at age 30 had twice the risk of breast cancer of a man weighing less than 60 kg at that age. Serum estrone levels were positively, and sex-hormone-binding globulin levels were negatively, related to body weight, and we interpret the greater weight of the cases as suggesting that the underlying risk factor is an increased exposure to bioavailable estrogen. None of the differences observed between cases and controls for either the serum or urinary hormone levels was, however, statistically significant and there did not appear to be any large absolute excess of estrogens or deficit of testosterone in the cases. This apparent contradiction may be explained by the fact that there was little difference in weight between the cases and controls at the time of sampling.
 ...
PMID:A case-control study of male breast cancer. 334 11

On the basis of information obtained from a population-based cancer registry in Sweden, male patients with breast cancer (n = 95) were found to have experienced significantly more brain concussions and skull fractures than male patients with lung cancer (n = 383) or malignant lymphoma (n = 69). Other risk factors significantly associated with breast cancer among men were drug treatment associated with prolactin elevations, radiation treatment, family history of breast cancer among first-degree relatives, a history of gynecomastia, gonadal injury, and treatment for inguinal hernias. The results confirm some previously described risk factors for male breast cancer and suggest that events elevating plasma prolactin (e.g., drugs, brain concussions, and skull fractures) and events predisposing for inguinal hernias may be new risk factors for the disease. Using hospital charts is likely to underestimate exposure for different risk factors; therefore, the results need to be confirmed in studies that directly retrieve information. However, such studies are difficult or impossible to undertake in most countries because the disease is so rare.
 ...
PMID:Head trauma and exposure to prolactin-elevating drugs as risk factors for male breast cancer. 337 57

A secreted glycoprotein with a molecular weight of 52,000 is induced by estrogen in breast cancer cells and has been purified to prepare monoclonal antibodies. The protein has been detected in some breast cancers but not in normal breast and uterus. In order to study its potential value as a marker, we have tested by immunohistochemistry frozen sections of several normal and malignant tissues and of benign mastopathies. Among different tissues tested, the Mr 52,000 protein was detected only in liver, sweat glands, and some sebaceous glands, and in malignant melanomas and some breast tumors. Other estrogen-responsive tissues (ovary, placenta, endometrium, etc.) gave negative results. Immunoradiometric assay of the Mr 52,000 protein in biological fluid revealed an elevated concentration in cyst fluid (0.5 to 7.4 micrograms/ml), pleural effusions of certain metastatic breast cancer, and sweat. By immunohistochemistry, the Mr 52,000 antigen was also detected in 42% of 129 benign mastopathies. Gynecomastia, fibrous disease, fibroadenoma, and adenosis were mainly negative, whereas ductal hyperplasia and cysts were positive. The Mr 52,000 protein was found mostly in proliferative ducts and in cysts but not in lobular hyperplasia and nonproliferative lesions without cyst. More Mr 52,000 protein was found in postmenopausal patients than in premenopausal patients. We conclude that the Mr 52,000 protein is a marker associated with mammary cysts and proliferative ducts. On the basis of the increased risk of breast cancer in proliferative mastopathies, we suggest that the Mr 52,000 protein is useful for predicting high-risk mastopathies acting as a marker associated with the proliferation of ductal tissue.
 ...
PMID:Distribution of the Mr 52,000 estrogen-regulated protein in benign breast diseases and other tissues by immunohistochemistry. 370 98

HCG and its subunits alpha and beta are produced by trophoblastic cancers constituting an index of early detection and monitoring for these tumors. Unlike HCG-alpha, we can obtain specific HCG and HCG-beta assays with LH-neutralized antiserum. Many normal non-trophoblastic tissues exhibit a HCG-like immunoreactivity. All choriocarcinomatous testicular tumors produce HCG and HCG-beta. Half of all testicular teratomas produce HCG and its subunits while a third of all seminomas exhibit an HCG-like immunoreactivity, whether choriocarcinomatous component is present or not. Serum HCG levels are elevated in seminomas (5 to 22%) as well as teratomas '55 to 89%). Less than 15% of breast, digestive and lung cancers have increased serum levels of HCG and/or its 2 subunits. HCG is most often produced by undifferentiated lung cancers, hepatoblastomas and adrenal carcinomas. There is usually a parallel relation between these serum levels and the clinical evolution of the disease under chemotherapy. In breast cancer, these levels do not constitue a "prognosis index". HCG production by non-trophoblastic tumors can induce clinical symptoms such as precocious puberty and gynecomastia.
 ...
PMID:[Are chorionic gonadotropin (HCG) and its alpha and beta subunits useful markers in non-trophoblastic tumors?]. 608 36

Two monoclonal antibodies were produced in mice immunized with the human breast carcinoma cell line MCF-7. One antibody (24-17.1) reacted with MCF-7 and other breast tumor cell lines and detected an antigen of Mr 95,000. This antigen was not breast-specific because other tumor cell lines were also reactive. The second antibody (24-17.2) detected an antigen of Mr 100,000 (initially appearing to be specific for breast tissue and possibly for breast carcinomas) which was present on 10 of 10 malignant breast lines and absent from 41 of 43 other cell lines of differing origins. The antigen could not be detected by absorption or a direct test on normal tissues (liver, kidney, heart, spleen) or on lymphocytes. In addition, the 24-17.2 antibody reacted absorptively with 12 of 13 fresh breast carcinoma samples but not with fresh colon carcinoma samples. The 100,000-Mr antigen detected by the 24-17.2 antibody appeared to be distinct from the other components of normal breast, such as casein, lactalbumin, or milk fat globulin protein. This evidence indicated that the 24-17.2 antibody detected a human breast carcinoma-associated antigen (HBCAA). However, further histologic studies were used to determine the cellular distribution of the HBCAA, which was found on malignant breast epithelium, the epithelium of gynecomastia, and in lesser amounts and differently distributed on normal breast epithelium. The antigen was also found in several other tissues; nonetheless, the anti-HBCAA could be detected in increased amounts in the sera of patients with breast cancer.
 ...
PMID:A human breast tissue-associated antigen detected by a monoclonal antibody. 618 62

The case is reported of a 48-year-old man who, 26 years after treatment for a hypophyseal tumor and 11 years after the onset of bilateral gynecomastia, developed cancer of the left breast. Ten years after the first breast cancer operation a new cancer developed in his right breast. Hormonal investigation at the time of the second breast cancer operation revealed a low S-FSH and a relative estrogen excess compared to testosterone. Values of thyroid and adrenal hormones were essentially normal, while P-prolactin was elevated. Stimulatory tests of the hypophyseal function were in accordance with a partial hypophyseal insufficiency affecting the hypophyseal-gonadal axis. Also, a weak elevation of S-HGH was noted by an insulin tolerance test. Immunohistochemical analysis of the pituitary tumor 36 years later showed that the tumor could be classified as a prolactinoma. Cytogenetic analysis revealed a normal male chromosome karyotype.
 ...
PMID:Hypophyseal tumor and gynecomastia preceding bilateral breast cancer development in a man. 670 24


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>